Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth

Pediatric Infectious Disease Journal

Volumn 31, Issue 12, 2012, Pages 1279-1283

  Wong, Frances L ^a   Hsu, Alice J ^b   Pham, Paul A ^b,c   Siberry, George K ^d   Hutton, Nancy ^e   Agwu, Allison L ^f  

^a KAISER PERMANENTE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e Divisions of General Pediatrics   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiretroviral; HIV; Perinatally HIV infected youth

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; RALTEGRAVIR;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PERINATAL INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84870885160     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31826fd3e7     Document Type: Article

References (12)

1. Brady MT, Oleske JM, Williams PL, et al.; Pediatric AIDS Clinical Trials Group219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53:86-94.
2. Patel K, Hernán MA, Williams PL, et al.; Pediatric AIDS Clinical Trials Group 219/219C Study Team. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46:507-515.
3. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2010;61:169-185.
4. Rudy BJ, Murphy DA, Harris DR, et al.; Adolescent Trials Network for HIV/AIDS Interventions. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS. 2010;24:97-104.
5. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18:682-689.
6. Cozzi-Lepri A, Phillips AN, Ruiz L, et al.; EuroSIDA Study Group. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007;21:721-732.
7. Agwu A, Lindsey JC, Ferguson K, et al.; Pediatric AIDS Clinical Trials Group 381 Study Team. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS. 2008;22:545-552.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138-145.
9. Van Dyke RB, Patel K, Siberry GK, et al.; Pediatric HIV/AIDS Cohort Study. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. 2011;57:165-173.
10. Murphy DA, Belzer M, Durako SJ, et al.; Adolescent Medicine HIV/AIDS Research Network. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med. 2005;159:764-770.
11. Legrand FA, Abadi J, Jordan KA, et al. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS. 2005;19:1575-1585.
12. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. August 11, 2011. Available at: http://aidsinfo.nih.gov/Content-Files/ PediatricGuidelines.pdf. Accessed April 3, 2011.